Saved local watchlist · Deprioritization mentions · sorted by registry update date
Candidate queue
877 active trial–asset records · showing latest 25 · no composite ranking
An ingestion window is pending. Refresh resumes the next page.
| Asset / trial | Sponsor / phase | Status / stopping reason | Independent scores | Source |
|---|---|---|---|---|
| TozuleristideNCT05316688 | University of WashingtonPHASE1, PHASE2 | TERMINATED Terminated due to suboptimal delineation of fluorescence between tumor and native oral cavity mucosa. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-16 |
| PembrolizumabNCT05764395 | Vanderbilt-Ingram Cancer CenterPHASE2 | TERMINATED Drug unavailable | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-16 |
| RigosertibNCT05764395 | Vanderbilt-Ingram Cancer CenterPHASE2 | TERMINATED Drug unavailable | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-16 |
| RuxolitinibNCT06397313 | Ryvu Therapeutics SAPHASE2 | TERMINATED Sponsor decision | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-16 |
| RVU120NCT06397313 | Ryvu Therapeutics SAPHASE2 | TERMINATED Sponsor decision | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-16 |
| UCB3101NCT06555601 | UCB Biopharma SRLPHASE1 | TERMINATED sponsor decision | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-16 |
| FludarabineNCT06968195 | Roswell Park Cancer InstitutePHASE1 | SUSPENDED awaiting agreement with Sponsor | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-15 |
| CyclophosphamideNCT06968195 | Roswell Park Cancer InstitutePHASE1 | SUSPENDED awaiting agreement with Sponsor | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-15 |
| Anti-GPC3-CAR Autologous T LymphocytesNCT06968195 | Roswell Park Cancer InstitutePHASE1 | SUSPENDED awaiting agreement with Sponsor | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-15 |
| Aspirin 325mgNCT05080946 | H. Lee Moffitt Cancer Center and Research InstituteEARLY_PHASE1 | SUSPENDED Study drug is expiring. Will reopen when new drug is received. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-15 |
| T-Cell therapyNCT05378464 | H. Lee Moffitt Cancer Center and Research InstitutePHASE1 | SUSPENDED Wait for the DLT period with our current patient and will not be enrolling any more. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-15 |
| PepinemabNCT05378464 | H. Lee Moffitt Cancer Center and Research InstitutePHASE1 | SUSPENDED Wait for the DLT period with our current patient and will not be enrolling any more. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-15 |
| TrastuzumabNCT05378464 | H. Lee Moffitt Cancer Center and Research InstitutePHASE1 | SUSPENDED Wait for the DLT period with our current patient and will not be enrolling any more. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-15 |
| Dendritic Cell (DC1) VaccineNCT05378464 | H. Lee Moffitt Cancer Center and Research InstitutePHASE1 | SUSPENDED Wait for the DLT period with our current patient and will not be enrolling any more. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-15 |
| Cetuximab Sarotalocan SodiumNCT06943664 | Roswell Park Cancer InstitutePHASE2 | WITHDRAWN Lack of funding | ScienceUnknown SafetyUnknown Strategic-abandonment likelihood75 Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2026-09-15 |
| CemiplimabNCT06943664 | Roswell Park Cancer InstitutePHASE2 | WITHDRAWN Lack of funding | ScienceUnknown SafetyUnknown Strategic-abandonment likelihood75 Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2026-09-15 |
| ARGX-119NCT06441682 | argenxPHASE2 | TERMINATED The study was terminated following review of interim data indicating that continuation was unlikely to demonstrate a clinically meaningful treatment effect. The decision was made to minimize unnecessary participant burden. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-15 |
| TobemstomigNCT05908786 | Hoffmann-La RochePHASE1, PHASE2 | TERMINATED Study was closed early as the sponsor decided not to continue development of certain treatment combinations. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-15 |
| TiragolumabNCT05908786 | Hoffmann-La RochePHASE1, PHASE2 | TERMINATED Study was closed early as the sponsor decided not to continue development of certain treatment combinations. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-15 |
| BevacizumabNCT05908786 | Hoffmann-La RochePHASE1, PHASE2 | TERMINATED Study was closed early as the sponsor decided not to continue development of certain treatment combinations. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-15 |
| AtezolizumabNCT05908786 | Hoffmann-La RochePHASE1, PHASE2 | TERMINATED Study was closed early as the sponsor decided not to continue development of certain treatment combinations. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-15 |
| EsketamineNCT06051227 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)PHASE3 | TERMINATED slow recruitment. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2026-09-15 |
| Fentanyl CitrateNCT06051227 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)PHASE3 | TERMINATED slow recruitment. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2026-09-15 |
| Pfizer-BioNTech COVID-19 mRNA vaccineNCT05876377 | PfizerPhase unknown | TERMINATED Study discontinued due to questions of data validity and bias in data which would limit causal inference and estimation of vaccine effectiveness. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-15 |
| CarboplatinNCT05403723 | University of Maryland, BaltimorePHASE1 | SUSPENDED PI changed institution. Not yet approved at current location. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-14 |
Recent ingestion runs
| Source | Studies seen | Candidate writes | Status / finished |
|---|---|---|---|
| pubmed | 240 | 100 | finished2026-09-21T03:58:28.397783+00:00 |
| pubmed | 0 | 0 | failed2026-09-21T03:48:59.232056+00:00 |
| sec | 0 | 0 | finished2026-09-21T03:48:59.212906+00:00 |
| ClinicalTrials.gov | 300 | 258 | partial2026-09-21T03:48:59.189357+00:00 |
| ClinicalTrials.gov | 300 | 305 | Legacy run2026-09-21T03:45:47.341408+00:00 |
| ClinicalTrials.gov | 300 | 348 | Legacy run2026-09-21T03:38:48.082427+00:00 |